Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Nov 9, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...
- Oct 26, 2015
Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Oct 26, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
-
Oct 19, 2015Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
-
Oct 16, 2015
Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
-
Oct 15, 2015
Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...
-
Oct 8, 2015
Eisai Inc. announced the decision of the National Comprehensive Cancer Network® (NCCN®) to recommend LENVIMA™ (lenvatinib) as the preferred agent for the treatment of patients with progressive...
- Sep 28, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for eribulin mesylate (eribulin) being evaluated...
- Sep 24, 2015Eisai, CancerCare®, Cancer Support Community®, Cornucopia Cancer Support Center™ and Meals on Wheels America Continue their Commitment to Providing Meal Assistance to Enable Loved Ones to Spend More Quality Time Together
Magnolia Meals at Home®, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now helping those living with thyroid cancer. Sponsored...
-
Jul 31, 2015Clinical trial will explore whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San Diego,...
